Dermata Therapeutics Warrant
DRMAW
5 hedge funds and large institutions have $5.42K invested in Dermata Therapeutics Warrant in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and closing their positions.
25% more funds holding
Funds holding: 4 → 5 (+1)
9.61% less ownership
Funds ownership: 11.61% → 2% (-9.6%)
30% less capital invested
Capital invested by funds: $7.7K → $5.42K (-$2.27K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$2 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$4.69K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$29 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BFM
1
Boothbay Fund Management
New York
| $4.93K | – | – | – |
|
|
WAM
2
Warberg Asset Management
Winnetka,
Illinois
| $285 | – | – | – |
|
|
AC
3
Armistice Capital
New York
| $193 | -$4.69K | -304,688 | -94% |
|
|
4
UBS Group
Zurich,
Switzerland
| $15 | -$29 | -1,868 | -56% |
|
|
5
Bank of America
Charlotte,
North Carolina
| $1 | +$2 | +100 | New |
|
DRMAW Hedge Fund Activity: Q1 2024 in Review
5 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics Warrant (DRMAW) for Q1 2024, worth a combined $5.42K — down 30% from $7.7K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new DRMAW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Bank of America, opening a new position worth an estimated $2. The largest seller was Armistice Capital, cutting an estimated $4.69K.
- 5 institutional investors held Dermata Therapeutics Warrant (DRMAW) as of Q1 2024, up from 4 in Q4 2023.
- Funds reported $5.42K of Dermata Therapeutics Warrant stock for Q1 2024, down 30% quarter-over-quarter.
- 1 fund opened new Dermata Therapeutics Warrant positions in Q1 2024 and 0 closed out, a net change of +1 holder.
- The largest Dermata Therapeutics Warrant buyer in Q1 2024 was Bank of America, an estimated $2 added.
- The largest Dermata Therapeutics Warrant seller in Q1 2024 was Armistice Capital, an estimated $4.69K sold.
Based on aggregated 13F filings for Q1 2024.